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Recent selected developments of the molecular science of prostate cancer (PrCa) biology 
and radiation oncology are reviewed. We present potential targets for molecular integration 
treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular 
treatment in combination with RT for patient care. We provide a synopsis of the information to 
date regarding molecular biology of PrCa, and potential integrated research strategy for improved 
treatment of PrCa. Many patients with early-stage disease at presentation can be treated 
effectively with androgen ablation treatment, surgery, or RT. However, a significant portion of 
men are diagnosed with advanced stage/high-risk disease and these patients progress despite 
curative therapeutic intervention. Unfortunately, management options for these patients are 
limited and are not always successful including treatment for hormone refractory disease. In 
this review, we focus on molecules of extracellular matrix component, apoptosis, androgen 
receptor, RUNX, and DNA methylation. Expanding our knowledge of the molecular biology of 
PrCa will permit the development of novel treatment strategies integrated with RT to improve 
patient outcome
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as phosphatase tensin homolog deleted on chromosome 10 (PTEN), 
Nkx3.1, p27KIP1, p53, and retinoblastoma (pRb). These molecules 
may cooperate for malignant transformation, tumor development, 
metastasis, and HBT resistance (Mimeault and Batra, 2006). Thus, 
elucidating the mechanisms of malignant progression from andro-
gen dependence to independence and finding a molecular target for 
treatment of PrCa by increasing the efficacy of RT is an important 
strategy for improved management of PrCa (Bromfield et al., 2003).
In this review, we discuss the challenges that present to RT for 
PrCa. Several molecular mechanisms that may be important for the 
survival of PrCa cells are evaluated. We will focus on the biology of 
androgen receptor (AR), DNA methylation, and microenvironment 
and will evaluate their potential effect on radioresistance of PrCa. 
We hope to shed light in molecular targeting in combination of 
RT to improve outcome for treatment of patients with the disease.
Challenge to Rt
The optimal management of PrCa relies on appropriate risk catego-
rization. This is defined by pre-treatment prostate-specific antigen 
(PSA), clinical staging, imaging, when needed, and Gleason score 
on pathology review (Oesterling et al., 1995; Gleason and T.V.U.R. 
Group, 1997; Pisansky et al., 1997; Edge et al., 2010). In the future, 
somatic mutations may be used for classification (Kan et al., 2010). 
The use of RT in low-risk (T1–T2a, PSA 10 ng/ml and Gleason score 
6) and intermediate-risk (T1/T2, PSA 20 ng/ml and Gleason score 
7) disease is well established, with comparable results to surgery in 
the era of modern RT. In addition, cancer-related outcomes in many 
intermediate and advanced patients with RT are improved with the 
use of adjuvant hormonal therapy (Pollack et al., 1995). Benefits to 
sub-categories of patients with intermediate-risk   factors need to 
IntRoduCtIon
Prostate cancer (PrCa) is the most common non-cutaneous malig-
nant disease and the second leading cause of cancer-related deaths 
among men in the United States (Jemal et al., 2010). Incidence var-
ies considerably between countries and appears to be increasing as 
a result of more frequent and improved diagnostic tests, an aging 
population, and likely increase in the occurrence of the disease 
(Jemal et al., 2011). At presentation, PrCa is highly responsive to 
anti-androgen treatment (Isaacs, 1999; Heinlein and Chang, 2004). 
However, patients with long-term application of treatment can 
evolve to the disease resistant to androgen ablation (Wu et al., 2007). 
This is more commonly referred to as hormone refractory (HR) 
disease or castration resistant disease (Dehm and Tindall, 2006).
In addition to hormone ablation therapy (HBT), radiation 
therapy (RT) is an important primary treatment modality for 
localized PrCa, and recent advances in volumetric based intensity 
modulated radiation therapy (IMRT) and image guided radiation 
therapy (IGRT) have permitted RT dose escalation beyond 75 Gy 
with external therapy. This has reduced both biochemical failure rate 
and the development of metastasis (Pollack et al., 2002; Parker and 
Dearnaley, 2003; Pisansky, 2006). Despite these advances, patients 
with both intermediate and high-risk features can still relapse after 
definitive hormone treatment and/or RT (Catton et al., 2003). One 
possible reason for these failures from RT may be due to the intrin-
sic radioresistance of a subpopulation of prostate tumor clono-
gen within the tumor. PC contains a variety of heterogeneous cell 
subpopulations characterized by over expression of oncogenic 
proteins such as epidermal growth factor receptor (EGFR), sonic 
hedgehog, Wnt/β-catenin, c-Myc, Akt, and nuclear factor-kappaB 
(NF-κB) or inactivation of distinct tumor suppressor proteins such Frontiers in Oncology | Radiation Oncology    July 2011  | Volume 1  |  Article 17  |  2
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diagnosis is usually responsive to anti-androgen treatment. More 
advanced phases of the disease may become resistant to therapy 
with subsequent recurrence (Isaacs, 1999; Heinlein and Chang, 
2004). Synergism with HDT and RT has been shown in several 
clinical trials (Table 1). Patients receiving HBT and RT have an 
improved clinical outcome validated by several prognostic factors 
including PSA, local control, development of distant metastasis, 
and overall survival compared to patients receiving RT as mono-
therapy (Pollack et al., 1995; Bolla et al., 2002; Pilepich et al., 2005). 
For high-risk patients, clinical trials show that a combination of 
HBT (neoadjuvant and adjuvant) and curative RT has a better 
local control and disease-free survival for PrCa patients than RT 
alone (Pollack et al., 1999; Roach, 1999). Although the addition 
of HBT did not significantly improve freedom from biochemical 
failure survival or disease-free survival in all prostate cancer patients 
receiving dose-escalated RT, it did approach significance in high-
risk patient subgroup (Valicenti et al., 2011).
For high-risk, locally advanced prostate adenocarcinoma, the 
combination of RT with 2–3 year HBT by LH–RH agonists is cur-
rently the recommended treatment. In patients with intermediate-
risk of Gleason score 7 prostate adenocarcinoma, a short course of 
HBT administered before and during RT has been associated with 
a significant improvement in local control, reduction in disease 
progression and overall survival (Pilepich et al., 2001). Moreover, 
in the RTOG 92-02 trial, treatment of locally advanced PrCa using 
long-term HBT is superior to short-term HBT for all end points 
including local failure, PSA recurrence, and distance metastasis 
except survival (Table 2). However, for patients with Gleason score 
of 8 to 10, a survival advantage for long-term HBT plus RT was 
shown in these high-risk patients (Hanks et al., 2003; Horwitz et al., 
2008). A specific survival benefit has been shown in several rand-
omized trials compared with RT alone. In the RTOG 85-31 phase 
III trial, RT alone was compared with RT and Goserelin acetate 
(Zoladex). A decrease of specific mortality at 10 years from 22 to 
16% (P1/40.0052) was demonstrated in the RT/HBT combina-
tion arm (Pilepich et al., 2005). In the EORTC 22863 trial, RT in 
combined with hormone therapy showed a 15% absolute specific 
survival advantage at 5 years compared to RT alone (94 versus 79%, 
be elucidated in the era of dose-escalated RT. Because of low α/β 
ratio, hypofractionated RT and brachytherapy using biologically 
equivalent doses also has the potential to improve the therapeutic 
index and to reduce overall treatment time (Brenner and Hall, 1999; 
Fowler et al., 2003). The sensitivity differential between tumor and 
normal tissues may favor the use of hypofractionated radiotherapy 
schedules for all patients with different stages of diseases. HBT 
improved the freedom from biochemical failure outcome index, 
but did not affect the low α/β value (Miralbell et al., 2011). In 
patients with high-risk disease (T3–T4, PSA > 20 ng/ml or Gleason 
score 7–10), radiation with HBT has become a standard treatment 
(Coblentz et al., 2002; Sandler, 2004). The challenges are to deter-
mine the optimal duration of HBT, assess the use of regional dose 
escalation, and to determine the benefit of chemotherapy and tar-
geted therapies that can be used with RT.
For regionally advanced PrCa, RT is a primary treatment option. 
RT is also an adjuvant treatment for prostatectomy (Szostak and 
Kyprianou, 2000). Successful treatment of PrCa patients by RT 
often depends on tumor radiosensitivity and the radiation tolerance 
of normal tissues. Systemic therapies that are cytotoxic and/or radi-
osensitizing are often combined with RT to improve therapeutic 
outcomes (Garzotto et al., 1999; Lin et al., 2003; Belka et al., 2004). 
This facilitates the use of RT with higher efficacy. Although the 
precise molecular mechanism by which radiation triggers cell death 
is not fully understood, the cytoplasmic membrane, DNA, and mol-
ecules associated with cell survival and cell death are major cellular 
targets (Higuchi, 2003; FitzGerald et al., 2004; Mishra, 2004). In 
spite of the development of modern RT technology including IMRT 
and IGRT, recurrence after RT can still occur albeit less common. 
A recent report claims that high percentage of patients treated for 
localized PrCa are at risk of recurrence, with half the recurrences 
occurring more than 10 years after treatment (Allen et al., 2007).
andRogen ReCeptoR and Its lIgand: RatIonales of 
hoRmone theRapy and Rt
Androgen receptor belongs to the nuclear receptor gene superfamily 
and mediates transcription of various genes important for disease 
maintenance (Feldman and Feldman, 2001). Early-stage PrCa at 
Table 1 | Comparison of treatment outcome of RT vs RT/HBT (percentage).
  Local failure  PSA failure  Distant met.  Overall survival  Reference
RT RT/HBT  p Value RT  RT/HBT p Value RT  RT/HBT  p Value RT  RT/HBT  p Value 
34 15  0.02  81 15  <0.001 13  3  0.4  90 97  0.4  Pollack et al. (1995)
38 23  <0.05  91 69  <0.001 39 24  0.0001  39 49  0.002  Pilepich et al. (2005)
7 1  <0.05  55 24  <0.05  29 10  <0.05  62 78  0.00002  Bolla et al. (2002)
Table 2 | Comparison of treatment outcomes of short-term HBT (SHRT) and RT with long-term HBT and RT (LHRT; percentage).
  Local failure  PSA failure  Distant met.  Overall survival  Reference
SHRT LHRT  p Value SHRT LHRT  p Value SHRT LHRT  p Value SHRT LHRT  p Value 
22.2 12.3  <0.001 68.1  51.96  <0.0001 22.8  14.8  0.001  51.6  53.9  0.359  Horwitz et al. (2008)
12.3  6.4  0.0001 55.5  28  <0.0001 17  11.5  0.0035  78.5  80  0.73  Hanks et al. (2003)www.frontiersin.org  July 2011  | Volume 1  |  Article 17  |  3
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  anti-androgen therapy with bicalutamide or flutamide in patients 
receiving combined androgen blockade. Serum PSA concentra-
tions are decreased by 50% or more when 50% of patients are 
withdrawn from flutamide and 29% of patients are withdrawn 
from bicalutamide (Veldscholte et al., 1990; Schellhammer et al., 
1997b). A supra-additive apoptosis with combination therapy has 
been shown in Dunning rat prostate tumors (Joon et al., 1997). This 
effect from the two modalities maximizes the apoptotic pathway for 
cellular death. However, concurrent anti-androgen treatment had 
no radiosensitization effect (Pollack et al., 2001). On the other hand, 
Zietman et al. (1997) using Shionogi SC-115 derived mouse cells in 
athymic male NCr/Sed (nu/nu) mice and in culture show androgen 
deprivation prior to radiation enhances the ability of irradiation to 
eradicate tumors in vivo. Androgen ablation can induced program 
celldeath in androgen-dependent prostate normal and cancerous 
cells (Isaacs et al., 1992). However, the HR cells induced by long-
term anti-androgen treatment appeared more radioresistant than 
the androgen-sensitive 22RV1 cells (Wu et al., 2007). Therefore it 
is important to study the interaction between drug and ionizing 
radiation (IR) in PrCa. The relationship of AR and AR ligand with 
RT also requires further investigation.
In summary, there appears to be a clear benefit to combined 
therapy with HBT and RT in selected intermediate-risk and high-
risk patients. However, there are both acute and long-term effects 
of hormone therapy that include the acceleration of cardiovascular 
disease, diabetes mellitus, and osteoporosis. One of the goals of 
understanding the molecular biology of PrCa is to evaluate the 
mechanism of the benefits of hormone therapy (cell adhesion 
modifier, etc.) and apply a targeted therapy with RT in order to 
temper the side effects of extended hormone treatment in patients 
with this disease. Novel therapies may mature and become validated 
with this approach to patient care.
IntegRIn and extRaCellulaR matRIx Component
Extracellular matrix component and their receptors play an impor-
tant role in cancer progression and metastasis (Hynes, 2002). 
Among these receptors, radiation appears to have a clear impact on 
integrin biology. Integrins are cell surface receptors which play an 
important role in oncogenesis, tumor aggression, and resistance to 
treatment as well as facilitating and promoting PrCa growth (Goel 
et al., 2009). The combination of integrin/cell adhesion inhibition 
and RT may become integral to improve patient outcome, espe-
cially for those patients with intermediate and high-risk features 
for tumor recurrence.
Integrin and its down stream signaling pathways have been 
shown to increase cell survival in response to IR (Onoda et al., 
1994; Meineke et al., 2002; Abdollahi et al., 2005; Cordes et al., 
2006; Park et al., 2008). Interactions between cells and ECM are 
P1/40.0001; Bolla et al., 2002). In this trial, HBT consisted of a total 
androgen blockade with an anti-androgen (Cyproterone acetate) 
and a LH–RH agonist (Goserelin acetate) for 1 month followed 
by the LH–RH agonist alone (Goserelin acetate) for 3 years. HBT 
started on the first day of RT in the combination treatment arm. 
In the RTOG 86-10 trial, HBT began 2 months before the start of 
RT and continued during RT. HBT consisted of a total androgen 
blockade with flutamide and Goserelin acetate. In this study, specific 
mortality was also decreased in the combined treatment arm with 
10 years of absolute benefit of 8% (77 versus 64%, P1/40.01; Roach 
et al., 2008). This observation is confirmed in two other reports. 
HBT as the only therapy for locally advanced PrCa failed to provide 
as efficient disease control as combined treatments (Janoff et al., 
2005; Widmark et al., 2009). As shown in the TROG 96.01 trial, for 
locally advanced prostate cancer, particularly in men without nodal 
metastases or pre-existing metabolic comorbidities that could be 
exacerbated by prolonged HBT, a short-term (6 months) treatment 
of neoadjuvant HBT combined with RT has been shown to be an 
effective treatment option (Denham et al., 2011).
Bicalutamide (Casodex), flutamide, and nilutamide are antago-
nists of AR and block androgen-regulated PrCa cell growth. In 
combination with a LH–RH agonist analog, bicalutamide has been 
shown to result in longer median survival than flutamide with bet-
ter tolerance (Schellhammer et al., 1997a). Bicalutamide can also be 
used at low doses in the treatment of metastatic PrCa when used in 
combination with a LH–RH agonist, thereby providing a complete 
androgen blockade. Moreover, bicalutamide decreases the risk of 
fracture by maintaining bone mineral density, which is lost by LH–
RH analogs (Boccardo et al., 1999; Shahinian et al., 2005). Recently, 
a phase III study demonstrated an improved overall survival as 
achieved by using adjuvant high-dose bicalutamide following RT 
compared to RT alone (69.6 versus 57.6%, P1/40.03) in a subgroup 
of patients with locally advanced PrCa after a median follow-up 
of 7.2 years (McLeod et al., 2006; See and Tyrrell, 2006). The gain 
in survival is comparable to the benefit from HBT by a LH–RH 
agonist in association with RT in the RTOG 85-31 study for high-
risk PrCa (Pilepich et al., 2005). In two other clinical trial reports, 
the benefit of neoadjuvant HBT and RT is established compared 
to HBT as monotherapy (Table 3), thus further demonstrating 
synergism between HBT and RT in high-risk patients (Zagars et al., 
2001; Widmark et al., 2009). Whether concomitant treatment with 
bicalutamide and RT results in an enhanced radiosensitivity of 
tumor cells responding to bicalutamide is still open to question.
Although not uniformly seen using clonogenic assays, there 
is evidence that HBT can sensitize prostate cancer cells to RT 
in in vitro models. The antagonistic radiation-drug interaction 
observed in LNCaP cells is of significance in RT–bicalutamide treat-
ments directed against AR expressing tumors. PSA decreases with 
Table 3 | Comparison of treatment outcomes of HBT and HBT/RT (percentage).
  Local failure  PSA failure  Distant met.  Overall survival  Reference
HBT RT/HBT p Value HBT  RT/HBT p Value  HBT  RT/HBT  p Value HBT RT/HBT  p Value 
51  21  0.001 75  20  <0.001 44  15  0.006  46  67  0.008 Zagars et al. (2001) 
38 23  <0.05  74.7 25.9  <0.001  39  24  0.0001  60.6 70.4  0.004  Widmark et al. (2009)Frontiers in Oncology | Radiation Oncology    July 2011  | Volume 1  |  Article 17  |  4
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treatment application. Identifying the optimal microenvironmental 
strategy for targeted therapies will be crucial in validating their util-
ity and establishing treatment sequence strategies moving forward.
As noted, we now know integrin expression is negatively affected 
by relatively high-dose RT. Simon et al. (2005) demonstrated that 
2500 cGy delivered in a hypofractionation treatment platform 
inhibits β1 integrin expression in DU-145 and PC-3 PrCa cells. 
This was not seen at lower doses of RT. Several reports indicate 
that the presence of β3 and β1 integrin in PrCa cells further pro-
motes resistance to radiation treatment as well as promoting tumor 
growth kinetics. This implies that several biological factors may 
influence RT treatment response. Targeting these areas for addi-
tive therapies to facilitate cell kill during RT is an important area 
of translational science.
In addition to the integrin subunit presented above, growing 
reports are focusing on αv integrin and its effect on RT in cancers 
particularly as potential targets post-IR to inhibit angiogenesis in 
the tumor microenvironment. αv integrin partners with β1, β3, and 
β6 integrin subunits. Treatment with αv integrin antagonist pep-
tide and fractionated IR in PC-3 PrCa xenografts in BALB/c-nu/
nu mice leads to enhanced antiangiogenic and anti-tumor effect 
when compared with either treatment alone (Abdollahi et al., 
2005). Meanwhile, targeting αv could have direct effects on can-
cer cells, as several cancer cell types up-regulate αv integrin post-IR 
(Wild-Bode et al., 2001; Smith and Giorgio, 2004). Upregulated 
αv integrin could therefore be targeted in the primary tumor to 
enhance radiation effect (Cao et al., 2006). Interestingly, αvβ3 inte-
grin expression differs not only in cancer site, but also may vary 
in response to different qualities of IR such as heavy particles 
(Ogata et al., 2005).
antIapoptosIs moleCules suCh as bcl-2, p53, and 
suRvIvIn
Ionizing radiation-induced cell death can proceed via several 
pathways such as apoptosis, mitotic catastrophe, necrosis, and 
autophagy (Kim et al., 2006; Zhang et al., 2006; Kroemer et al., 
2009). Apoptosis is an active process characterized by programmed 
cell death in which a cascade of events is triggered in response 
to cellular stress such as radiation (Nagata, 1997). Several lines of 
evidence suggest that progression from androgen-dependent to 
androgen-independent disease is associated with resistance to apo-
ptosis and altered expression of caspases and expression of inhibitor 
of apoptosis (IAP) proteins (McEleny et al., 2002). Understanding 
which apoptotic pathways become altered and by what mechanism, 
for example genetic or epigenetic, may provide a rationale for tar-
geting the cell death machinery in HR PrCa.
In PrCa, changes in the expression level of several molecules have 
been identified in various components of the apoptotic cascade. 
For instance, bcl-2 over-expresses in patients with locally advanced 
or metastatic PrCa receiving hormonal therapy (Colombel et al., 
1993; Krajewska et al., 1996) and bcl-2-overexpressing prostate 
carcinoma cell lines are associated with a reduced apoptotic 
response following treatment with various  chemotherapeu-
tic agents and IR (Kyprianou et al., 1997). Down-regulation of 
DAB2IP in PrCa cells showed resistance to IR-induced apoptosis 
due to a significantly higher levels of anti-apoptotic proteins bcl-2 
and STAT3, and decrease in the expression levels of pro-apoptotic 
known to modulate sensitivity to radiation and drug in vari-
ous types of tumors, such as breast, colon, ovaries, and prostate 
tumors (Fujita et al., 1995; Cance et al., 2000; Graff et al., 2001; 
Oktay et al., 2003). At low doses of RT cell adhesion molecules 
may be upregulated. Human lung carcinoma cells grown on 
fibronectin significantly elevated clonogenic survival as well as 
prolonged G2 arrest after RT (Cordes et al., 2003). Investigators 
also demonstrated that β1 integrin mediated signaling through 
cytoplasmic domains is critical for efficient cell survival after 
RT (Cordes et al., 2006). Using a human breast cancer xeno-
grafts model, inhibition of integrin function by antibody (AIIB2) 
enhances RT efficacy suggesting β1 integrin mediated radiore-
sistance in breast cancer (Park et al., 2008). In renal carcinoma 
cells, adherence to collagen (I) enhances radioresistance through 
Akt dependent mechanism (Krasny et al., 2010). The negative 
influence in survival by integrin expression is seen in glottic 
cancer and cervical cancer (Choi et al., 2006; Hazelbag et al., 
2007). IR upregulates the expression of β1 integrins and sub-
sequently the cell-matrix interaction of colorectal tumor cells 
in a dose dependent manner; most noted at low dose (Meineke 
et al., 2002). Combination therapy with αvβ3 integrin antago-
nists and teletherapy appear beneficial in local tumor therapy. 
Cilengitide, a αvβ3 integrin antagonist peptide, synergizes with 
radio- immunotherapy to increase efficacy and apoptosis in breast 
cancer cells (Burke et al., 2002). Similarly, Cao et al. (2006) have 
shown that combined treatment of αV siRNA and irradiation 
leads to increased radiosensitivity. In PrCa, treatment of epithe-
lial-versus mesenchymal-like cells by anti-αv integrin blocking 
antibody significantly decreases stoma-cell induced radiation 
resistance (Josson et al., 2010). ADAM9 (a disintegrin and met-
alloprotease) appears to play a crucial role in radiation resistance 
in part by altering E-cadherin and integrin expression in PrCa 
cells (Josson et al., 2011). Cell adhesion hence has significant 
influence in cell survival with RT across many disease sites. We 
have demonstrated that high-doses of RT inhibit the expres-
sion of β1 integrin in PrCa cells (Simon et al., 2005). In LNCaP 
cells stably transfected with β3 integrin, αvβ3 integrin increased 
radiation resistance after clinically relevant doses of 2–10 Gy 
and enhanced anchorage-independent growth after 5 Gy irra-
diation as evaluated in the clonogenic assay and the anchorage-
independent assays (Wang et al., 2007). Integrin function had 
no significant effect on AR expression. Hence the mechanism of 
resistance appears to be independent of receptor levels.
The biologic science of RT is revealing a provocative and devel-
oping relationship with cell adhesion. Although there is minimal 
influence on adhesion modulation in unirradiated tumor cells in 
the presence of androgen, bicalutamide significantly inhibited the 
adhesion response in irradiated cells thus reversing the effect of 
androgen (Wang et al., 2008). This suggests that bicalutamide may 
play a key role in adhesion modulation and possible tumor cell kill 
during RT, and, interestingly, may have little to no adhesion modu-
lation effect in untreated tissue in the presence of androgen. This 
further suggests that patients may benefit from adhesion modula-
tion during RT with very limited impact of this agent prior to treat-
ment in the presence of androgen. This is an important concept in 
clinical trials as biological therapies are tested in a phase 1 environ-
ment that may or may not identify the appropriate environment for www.frontiersin.org  July 2011  | Volume 1  |  Article 17  |  5
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under NF-κB inhibition (Sainz et al., 2008). Further study needs 
to be focused on the mechanism of IAP in regulating cell survival 
in response to IR.
epIgenetIC modIfICatIons – dna methylatIon
In addition to classical genetic abnormalities, epigenetic modifica-
tions have emerged as an important issue in the molecular pathol-
ogy of PrCa (Perry et al., 2006). So far, DNA methylation, histone 
modification and genomic imprinting are three major mechanisms 
for epigenetic modifications identified in PrCa. We focus on DNA 
methylation in this review because: (1) DNA methylation directly 
modifies specific gene transcription which subsequently controls 
the gene related cellular function (i.e., GSTP1, AR; Jarrard et al., 
1998; Kinoshita et al., 2000; Yegnasubramanian et al., 2004; Meiers 
et al., 2007); (2) histone modification by methylation at the residue 
lysine by EZH2 is linked to advanced hormone resistant metastatic 
PrCa (Kirmizis et al., 2004); and (3) genomic imprinting can be 
controlled by DNA methylation (i.e., p57 tumor suppressor gene, 
TSG; Lodygin et al., 2005).
DNA methylation is defined as an addition of a methyl (-CH3) 
group at the 5′-carbon on cytosine nucleotide adjacent to a guanine 
(CpG; Weber and Schubeler, 2007). DNA methylation is processed 
by various conserved enzymes named DNA MTases (DNMTs) that 
transfer -CH3 group from S-adenosylmethionine (SAM) to cova-
lently bind at cytosine residues in the promoter of a target gene. 
SAM is produced through a folate and cobalamin dependent path-
way (Dobosy et al., 2007). DNA hypermethylation is one of the 
known epigenetic modifications and plays an important role in the 
down-regulation of gene expression critical for protection against 
PrCa (Esteller, 2005). It is associated with an inactive chromatin 
state and is often with repressed gene expression activity (Klose 
and Bird, 2006; Weber and Schubeler, 2007). Abnormal changes in 
Global DNA methylation have been linked to initiation of various 
cancer cells (Baylin and Ohm, 2006; Weidman et al., 2007).
The function of DNA methylation is diversified in a variety of 
tissues including normal and neoplastic cells. Disruption of DNA 
methylation by inactivation of DNMTs is lethal to embryo in early 
development (Li et al., 1992). In cancer cells, DNA methylation has 
a divergent effect. Hypermethylation occurs in the promoters of 
tumor suppressor and other genes resulting in silencing the asso-
ciated gene in the absence of a mutation or deletion. In PrCa, the 
DNMT1 has 2- to 3-fold higher enzymatic activities compared to 
that in BPH and normal tissue (Patra et al., 2002). DNMT2 and 
DNMT3a are upregulated in HR PrCa cells indicating the impor-
tance of alternation of methylation for development of androgen 
resistance PrCa (Pang et al., 2006).
Methylation of AR promoter CpG island is associated with the 
development of HR PrCa. Jarrard et al. (1998) using Southern 
Blot with methylation-sensitive restriction enzymes and 
  methylation-specific PCR found aberrant methylation in the AR 
negative cells DU-145 and DuPro while in AR positive cells LNCaP 
shows no methylation. Treatment of DuPro with a demethylating 
agent 5-aza-2′ deoxycytidine induces the reexpression of AR RNA 
(Jarrard et al., 1998).
So far, more than 50 genes have been reported to be hyper-
methylated in PrCa (Li et al., 2004; Nelson et al., 2007). Many of 
these genes are often mutated or deleted in PrCa suggesting the 
proteins   caspase-3, caspase-8, and caspase-9 (Kong et al., 2010). 
P53, which controls the expression of several pro-apoptotic genes 
such as BAX, CDKN1A, and MDM2, induces cell cycle arrest or 
apoptosis in response to DNA damage (Wang et al., 2004). TP53 
mutations are uncommon in early invasive prostate carcinoma 
but occur frequently in advanced stages of disease (Navone et al., 
1993). Expression of bcl-2 and p53 was associated with treatment 
failure after external beam RT (Scherr et al., 1999). Co-staining 
for p53 and bcl-2 is a potential biomarker for PrCa progression, 
poor prognosis and recurrence (Moul et al., 1996; Matsushima 
et al., 1997). Tissue microarrays of normal, and cancerous pros-
tates have identified bcl-2, FLIP, clustrin (CLU), mothers against 
DPP homology 4 (SMAD4), death-  associated protein (DAP), and 
p53-induced protein PIGPC1 (PERP) as down-regulated in PrCa 
(Yu et al., 2004). Interestingly, over expression of E2F1 in combina-
tion with RT treatment abrogated radiation-induced bcl-2 protein 
expression and caused a potent radiosensitizing effect, irrespective 
of p53 and AR functional status (Udayakumar et al., 2011). Such 
data highlights the importance of both pro-apoptotic and anti-
apoptotic molecules in prostate carcinogenesis and progression.
Survivin is a member of the IAP gene family whose expression 
is associated with conservation of cell division and direct inhibi-
tion of caspases (Altieri, 2006). Upregulation of survivin expres-
sion has been shown in glioblastoma, colon, and pancreatic cells 
(Chakravarti et al., 2004; Sreevalsan et al., 2009). Intratumoral 
injection of an antisense against survivin or of an adenovirus 
expressing a dominant negative form of survivin, T34A, inhibits 
tumor growth and enhances sensitivity to anti-androgen therapy 
(O’Connor et al., 2000; Zhang et al., 2005). Signaling pathways 
regulating survivin involve wild-type p53 and the Rb tumor sup-
pressor that transcriptionally represses survivin (Jiang et al., 2004). 
Recent evidence suggests a strong relationship between survivin 
and PrCa radiation treatment. Over expression of survivin is asso-
ciated with a significantly increased risk for the subsequent devel-
opment of distant metastasis (p = 0.016) in early-stage (T1/T2) 
PrCa treated by definitive RT (Zhang et al., 2010a). Inhibition of 
cell survival and potentiated radiation cell killing by soy isoflavones 
in PrCa cells, in vitro and in vivo, is correlated with inhibition of 
survivin (Raffoul et al., 2007). While cytoplasmic over expres-
sion of survivin was associated with an increased rate of local 
progression in patients with locally advanced PrCa, nuclear over 
expression of survivin was associated with improved overall and 
PrCa survival in patients treated on RTOG 8610 (Zhang et al., 
2009). This might be the result from the complexity of survivin’s 
role and differential responses to IR of heterogeneous PrCa cells. 
Some authors have argued that apoptosis is not the predominant 
form of PrCa cell death after exposure to IR (Steel, 2001). Bristow 
et al. have shown that terminal growth arrest instead of apoptosis 
is actually the dominant mechanism of radiation cell kill in PrCa 
cells (Bromfield et al., 2003). LNCaP cells supra-additive apoptosis 
does not translate into radiosensitization by clonogenic survival 
(Pollack et al., 2001). Other molecular mechanisms may play an 
important role in protecting PrCa cells from IR-induced toxic-
ity. For example, melatonin expression fails to enhance PrCa cell 
death from IR duo to glutathione content. In contrast, melatonin 
significantly enhances hrTNFalpha induced cell death by down-
regulation of Bcl-2 and survivin and stimulation of apoptosis Frontiers in Oncology | Radiation Oncology    July 2011  | Volume 1  |  Article 17  |  6
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prCa metastasIs followIng RadIatIon
One of the challenges in treating advanced PrCa is whether or not 
radiopharmaceuticals could eradicate tumor cells that have metas-
tasized to the bone microenvironment. Micrometastatic cells have 
been identified in bone marrow in an onco-niche and studies are 
needed to understand if such are resistant to radiation treatment 
(Tu et al., 2010). Multiple regulatory networks contribute to pro-
liferation of PrCa cells, survival, metastasis, and homing of PrCa 
cells to bone (Altieri et al., 2009; Pratap et al., 2011). In addition 
to the factors described above, a transcriptional based regulatory 
network involves the bone essential transcription factor, Runx2, 
which is abnormally expressed in PrCa cells and has been cor-
related with metastatic bone disease (Akech et al., 2010; Baniwal 
et al., 2010). Runx2 expression is restricted to mesenchymal stem 
cells and marks them for commitment to the osteogenic lineage 
cells, but is absent from normal epithelial cells of the prostate 
glands (Zaidi et al., 2007). The highest levels of Runx2 are observed 
in the most aggressive human metastatic cell lines producing both 
osteoclastic and osteoblastic lesions in prostate tumors that metas-
tasize to bone (Yang et al., 2001; Roudier et al., 2004; Akech et al., 
2010). However, in studies using the conditional PTEN deletion 
mouse model, cancer associated fibroblasts were isolated from the 
adenocarcinomas and a signature of genes identified that included 
high Runx2 expression levels (Liao et al., 2010). These observations 
suggest that Runx2 could support tumor growth, progression, and 
metastasis.
alteration of gene expression resulted from epigenetic silencing and 
genetic mutation. Among these, roughly a dozen are consistently 
affected in the vast majority of cases. These gene products involve 
the various molecules that directly control DNA damage repair 
(GSTP1), tumor suppressor, cell cycle control, cell adhesion, and 
signal transduction.
Analysis of the methylation of genes such as RASSF1A, RARB2, 
APC, and GSTP1 (Florl et al., 2004) or GSTP1, APC, and MDR1 
(Enokida et al., 2005) clearly discriminates between benign and 
cancerous tumors in the prostate. Hypermethylation silencing 
of TSG increases mutation rates and tumor progression (Jones 
and Baylin, 2002). Whereas hypermethylation of specific genes 
is evidently associated with an early phase of PrCa development, 
global DNA hypomethylation may be related to PrCa progres-
sion. Metastatic cases are characterized by pronounced decreases 
in overall methylcytosine content and, in particular, hypometh-
ylation of LINE-1 retrotransposons, which are almost com-
pletely methylated in normal cells (Florl et al., 2004). Localized 
cancers may even display an increase in overall methylation at 
cytosine, despite a low degree of retroelement hypomethylation 
(Yegnasubramanian et al., 2008). Likewise, over expression of 
cancer–testis antigen genes, which is regularly associated with 
hypomethylation of their promoters, is largely restricted to 
advanced stages of prostate adenocarcinoma (Yegnasubramanian 
et al., 2008). The consistency with which large-scale hypometh-
ylation is observed in metastatic cases suggests that the mecha-
nisms maintaining methylation at retroelements and other 
normally methylated sequences are regularly disturbed during 
PrCa progression.
Recent data also demonstrate a relationship between DNA 
methylation and response to RT. Point mutations in Keap1 gene 
lead to non-conservative amino acid substitutions in PrCa cells, 
novel transcriptional and posttranscriptional mechanisms of 
Keap1 inactivation, such as promoter CpG island hypermeth-
ylation and aberrant splicing of Keap1 in DU-145 cells, enhances 
Nrf2 activity and subsequently prevents cell sensitivity to 
 radiation-induced cell death (Zhang et al., 2010b). In breast can-
cer cells, the loss of Nrf2 increases radiation sensitivity via regula-
tion of antioxidant DNA responsive element (McDonald et al., 
2010). A single methylated gene can affect radiation sensitivity. In 
cervical cancer, methylation of p73 (tumor protein 73) increased 
significantly. Reactivation of p73 expression by demethylation 
treatment revealed the role of methylation in the regulation of 
p73 expression and plays an important role in regulation of cel-
lular radiosensitivity (Liu et al., 2004). Another important gene 
that can change cell sensitivity to IR, ATM, was also identified as 
a vital component of the signal transduction pathway activated 
by DNA damage (Shiloh, 2003; Lavin et al., 2005). U87 glioma 
cells with lower levels of ATM were more sensitive to IR (42-fold) 
than T98G glioma cells exhibiting normal levels of ATM protein. 
The ATM promoter in U87 cells was methylated. Demethylation 
treatment increases ATM protein levels in U87 cells and decreases 
their radiosensitivity (Roy et al., 2006). The methylation status 
of many other genes was also associated with radiosensitivity, 
e.g., suppressor of cytokine signaling 1 (SOCS1), suppressor 
of cytokine signaling 3 (SOCS3), and death-associated protein 
kinase (DAPK; Zhou et al., 2007; Leung et al., 2008).
FiguRE 1 | Summary of molecular mechanisms underlying 
radioresistance of PrCa. During RT, some cells survive after radiation. These 
cells play an important role in recurrence of prostate caner. Molecules 
discussed in this review were summarized. www.frontiersin.org  July 2011  | Volume 1  |  Article 17  |  7
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improved strategies for patient care in more advanced intermediate 
and high-risk patients. Since the disease remains largely chemo-
therapy naïve, PrCa is a good model to explore alternatives in 
patient care management with RT. As seen, cell adhesion modu-
lation, signaling pathway evaluation, and epigenetic models such 
as DNA methylation may prove to be important adjuncts in the 
clinical RT management of these patients (Figure 1). Alternatives 
to hormone management may likewise become important in 
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(Lim et al., 2010; Rucci and Teti, 2010). Runx2 also enhances cell 
growth and responses to androgen, TGFβ and BMP by forming 
complexes with hormone receptors and SMAD intracellular recep-
tors of TGFβ/BMP signaling that promote tumor growth (Baniwal 
et al., 2010; van der Deen et al., 2010). Another component of a 
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